Leukemia: A Review of Data from the ASH 2021 Meeting - Episode 2

ASH 2021: Key Data in Chronic Myeloid Leukemia

, ,

Shared insight on updates in the chronic myeloid leukemia treatment landscape following the ASH 2021 annual meeting.

EP. 1: ASH 2021: Novel Therapy in Acute Lymphocytic Leukemia
Now Viewing
EP. 2: ASH 2021: Key Data in Chronic Myeloid Leukemia
EP. 3: ASH 2021: Updates in the Chronic Lymphocytic Leukemia Treatment Landscape

Data from the following clinical trials are discussed:

  • 310: Efficacy and safety results from ASCEMBL, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib in patients with chronic myeloid leukemia in chronic phase after ≥2 tyrosine kinase inhibitors: update after 48 weeks
  • 307: Post hoc analysis of responses to ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) by baseline BCR-ABL1 level and baseline mutation status in the Optic trial

Supported in part by Takeda Oncology. Content developed independently by Onclive®.